NeuroSense Therapeutics Ltd. is a clinical-stage drug development company focused on developing treatments for neurodegenerative diseases. Its lead product candidate, PrimeC, is being developed for the treatment of ALS (amyotrophic lateral sclerosis). The company was incorporated in February 2017, has not yet commercialized any products, and has incurred significant net losses, including $11.1 million and $10.2 million for the years ended December 31, 2025 and 2024, respectively.
Look up NRSN using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on NRSN, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/NRSN (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.